Skip to content

Evaluating Piezo-ICSI. - The EPI Study.

Will Piezo-ICSI Increase Fertilization Rates Compared to Conventional ICSI? A Prospective Randomized Sibling Study.

Status
Suspended
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04669652
Enrollment
265
Registered
2020-12-17
Start date
2023-09-30
Completion date
2024-10-31
Last updated
2022-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, IVF

Keywords

ICSI, Fertilization, Piezo-ICSI, Oocyte, Blastocyst rate

Brief summary

Intracytoplasmic sperm injection (ICSI) has successfully been used to treat both severe male infertility and fertilization failure since its introduction in the early 1990´s. During the procedure a single sperm is injected into the cytoplasm of an oocyte to achieve fertilization. This technique is intrusive, has a relatively long learning curve and variable operator performance. A new injection technique called piezo-ICSI has recently been introduced. During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjections with less psychical stress applied on the oocytes than by the conventional technique. A recent analysis, based on data from 9 different studies comparing conventional ICSI and piezo-ICSI (17500 cases), showed a benefit of piezo. Unfortunately, proper randomized trials are missing from this analysis. The proposed study is a randomized controlled study carried out at two private IVF clinics. Eligible participants are patients undergoing ICSI treatment, with a minimum of 6 oocytes. The participants will act as their own controls, with their oocytes randomly and equally divided between injection by the investigated and the conventional technique. Whether piezo-ICSI is associated with improved success rates or reduction in adverse outcomes is at present unclear. Patients with fragile oocytes may benefit more from piezo-ICSI. In patients above 35 years, piezo-ICSI has been associated with a lower oocyte degeneration rate and an increased blastocyst rate. The aim of the study is to investigate whether the piezo-ICSI technique will result in more oocytes becoming normally fertilized compared to conventional ICSI. Another proposed benefit of piezo-ICSI lies in the standardization and simplification of the ICSI procedure. Making the injection procedure more independent of operator skill may result in a more robust and predictable laboratory output.

Interventions

During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.

Sponsors

Vitrolife
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

A sibling study randomizing oocytes to 2 study groups.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients receiving controlled ovarian stimulation with gonadotrophins needing ICSI for fertilizing oocytes. 2. Availability of at least six mature oocytes (MII) after oocyte pick-up. 3. Planned blastocyst culture.

Exclusion criteria

1. Intention to perform any form of preimplantation genetic testing 2. The use of IMSI or polarized light in the ICSI process 3. The use of assisted hatching prior to randomization. 4. Surgical sperm retrieval (SSR) patients. 5. Previous participation in this RCT 6. Concurrent participation in another investigation that can affect the primary outcome of this study. 7. Sperm sample with \<0.1million/ml or motility of \<2% after preparation. 8. Fertility preservation cycles. 9. If a day 2-4 transfer is planned 10. Use of vitrified oocytes.

Design outcomes

Primary

MeasureTime frameDescription
Fertilization rateOocytes will be observed over a period of 26 hours after the interventionNumber of normally fertilized oocytes per injected oocytes

Secondary

MeasureTime frameDescription
Percentage of 0 PN oocytesOocytes will be observed over a period of 26 hours after the interventionNumber of oocytes not fertilized (0 PN) after the procedure.
Percentage of 1 PN oocytes.Oocytes will be observed over a period of 26 hours after the interventionNumber of oocytes fertilized with one pronuclei (1 PN) after the procedure.
Percentage of >2PN oocytes.Oocytes will be observed over a period of 26 hours after the interventionNumber of oocytes fertilized with more than 2 pronuclei (\>2PN) after the procedure.
Differences in KID scores.Embryos will be observed over a period of 6 days after the procedureEmbryo development will be analysed using a mathematical models called KID (0-10 scale).
Percentage of degenerated oocytesOocytes will be observed over a period of 26 hours after the interventionNumber of oocytes that have degenerated after the procedure
Blastocyst rate (number of grade 3 or higher).Embryos will be observed over a period of 6 days after the procedureNumber of blastocysts with a morphological score of grade 3 or higher.
Percentage of cryopreserved blastocysts on day 5 and 6.Embryos will be observed over a period of 6 days after the procedureNumber of blastocysts cryopreserved on day 5 and day 6.
8. Utilization rate (Number of transferred and cryopreserved blastocysts). Utilization rateEmbryos will be observed over a period of 6 days after the procedureNumber of transferred and cryopreserved blastocysts
Differences in iDA scores.Embryos will be observed over a period of 6 days after the procedureEmbryo development will be analyzed using a artificial intelligence model, called iDA (0-10 scale).

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026